Role of SGLT2i in HF

Description

Outline -Heart Failure and Type 2 Diabetes Mellitus -T2DM treatments and HF -Pattern of HF in Kenya -Baseline characteristic differences in the trials -DAPA-HF Features -Drug development of SGLT2i

Objectives

Presenters

1. Dr. Harun Otieno
   Interventiional Cardiologist at AKUH Africa Heart Associates Nairobi, Kenya PASCAR East Vice President KSTH Vice chair
   Aga Khan University Hospital


2. Dr. Emma Karari
   Consultant Cardiologist
   University of Nairobi